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Life-history theory predicts that sexually reproducing organisms have evolved to resolve resource-
allocation trade-offs between growth/survival versus reproduction, and current versus future
reproduction. Malaria parasites replicate asexually in their vertebrate hosts, but must reproduce sexually
to infect vectors and be transmitted to new hosts. As different specialized stages are required for these
functions, the division of resources between these life-history components is a fundamental evolutionary
problem. Here, we test how drug-sensitive and drug-resistant isolates of the human malaria parasite
Plasmodium falciparum resolve the trade-off between in-host replication and between-host transmission
when exposed to treatment with anti-malarial drugs. Previous studies have shown that parasites increase
their investment in sexual stages when exposed to stressful conditions, such as drugs. However, we
demonstrate that sensitive parasites facultatively decrease their investment in sexual stages when exposed
to drugs. In contrast to previous studies, we tested parasites from a region where treatment with anti-
malarial drugs is common and transmission is seasonal. We hypothesize that when exposed to drugs,
parasites invest in their survival and future transmission by diverting resources from reproduction to repli-
cation. Furthermore, as drug-resistant parasites did not adjust their investment when exposed to drugs,
we suggest that parasites respond to changes in their proliferation (state) rather the presence of drugs.
Keywords: Plasmodium falciparum; life-history trade-offs; gametocyte conversion; anti-malarial drug
resistance; reproductive effort; resource allocation
1. INTRODUCTION
In its broadest sense, phenotypic plasticity is the ability of
a single genotype to produce different phenotypes in
different environments, through mechanisms such as
differential gene expression or epigenetic effects
(Schlichting & Pigliucci 1998). Phenotypic adjustment
can occur in response to changes in an individual’s extrin-
sic environment (e.g. appearance of predators) or
intrinsic state (e.g. parasite burden) and is considered
to be adaptive when it results in increased ﬁtness, through
enhanced survival or reproductive success (Schlichting &
Pigliucci 1998). The extent to which individuals can
adjust their behaviours or express different combinations
of traits is constrained by resource-allocation trade-offs
in which organisms have to split their ﬁnite resources
between the multiple processes (e.g. growth/survival,
reproduction) required to transmit gene copies to
subsequent generations (Roff 1992; Stearns 1992).
Life-history theory provides a solid foundation for
understanding plasticity in resource-allocation trade-offs
and can be used to explain and predict the evolutionary
consequences of environmental variation (Roff 1992;
Stearns 1992; Fischer et al. 2009; McNamara et al. 2009).
While adaptive phenotypic plasticity has been
thoroughly documented for metazoan taxa (such as
insects, birds and mammals), this concept has been lar-
gely overlooked for unicellular taxa such as malaria
(Plasmodium) parasites (Reece et al. 2009). Malaria para-
sites face many analogous selective pressures and
resource trade-offs to metazoans, and data suggest they
also have considerable plasticity in their resource-allo-
cation decisions (Paul et al. 2000; Reece et al. 2008,
2009). The value of an evolutionary approach for under-
standing how variation in the in-host environment
shapes within-infection dynamics and contributes to
virulence and transmission traits is increasingly being
recognized. Malaria parasites replicate asexually in the
circulation of their vertebrate hosts, but must produce
male and female sexual stages (termed gametocytes) to
transmit to vectors and subsequently infect new hosts.
As in-host replication and between-host transmission
are each achieved by different specialized forms, the div-
ision of resources between these life-history components
is a fundamental evolutionary problem (Koella & Antia
1995). This is analogous to the problem faced by
sexually reproducing organisms, in which the trade-off
between investing resources into reproduction
(reproductive effort) relative to growth and maintenance
is a major determinant of ﬁtness (Roff 1992;
Stearns 1992). * Author for correspondence (sarah.reece@ed.ac.uk).
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rodents and humans increase their investment in gameto-
cytes in response to host anaemia, changes in the age of
available red blood cells (RBCs) and exposure to anti-
malarial drugs (Trager & Gill 1992; Buckling et al.
1997, 1999a,b; Buckling & Read 1999; Trager et al.
1999; Reece et al. 2005). These observations have been
interpreted as environmental changes that are stressful
for parasites, to which they respond by diverting resources
to gametocytes to increase between-host transmission
(Taylor & Read 1997; Read & Taylor 2001). This ‘term-
inal investment’ is predicted by evolutionary theory when
changes in intrinsic state, the environment or availability
of resources reduce the probability of survival (Williams
1966). However, changes in the age of available RBCs
can result in parasites having more useable resources
(Paul & Brey 2003; Paul et al. 2003; Reece et al. 2005),
and parasites adopt the opposite to terminal investment
and are predicted to decrease investment in gametocytes
in response to competitive suppression in mixed infec-
tions (Mideo & Day 2008; Pollitt et al. submitted).
Therefore, parasites do not necessarily respond to stress
by increasing investment in gametocytes, and in situations
where ‘safety in numbers’ can facilitate in-host survival,
‘reproductive restraint’ is a better investment decision
(Mideo & Day 2008; Reece et al. 2009; Pollitt et al.
submitted). Here, we focus on testing whether parasites
also adopt reproductive restraint when treated with anti-
malarial drugs that suppress their proliferation.
The suggestion that malaria parasites alter investment
into gametocytes when exposed to drugs has received
mixed support. However, research has focused solely on
whether investment is increased or not adjusted (Puta &
Manyando 1997; Buckling et al. 1999b; Drakeley et al.
2006; Babiker et al. 2008; Peatey et al. 2009), and the
alternative possibility of decreased investment (repro-
ductive restraint) has been overlooked. Furthermore,
previous studies have focused on short exposures at
high doses that are insufﬁcient to clear infections but
still cause a rapid decline in parasite numbers. If rapid
decline in numbers is a reliable cue of a catastrophic situ-
ation, the potential for future transmission is low, and so
parasites are expected to adopt terminal investment.
Here, we test whether multiple lines of the human malaria
parasite Plasmodium falciparum adopt reproductive
restraint in response to exposure to two different anti-
malarial drugs that target asexual replication. We focus
on providing continuous sublethal stress by treating para-
sites with low doses of drugs across multiple replication
cycles. In endemic areas, malaria parasites face low
levels of anti-malarial drugs for a variety of reasons. For
example, recommended regimes can fail to eliminate
parasites because treatment success is inﬂuenced by para-
site density, and patients can be reinfected before
previous treatments are cleared (Adjuik et al. 2004;
Mutabingwa et al. 2005; Barnes et al. 2007). The latter
is especially likely under intermittent preventive treat-
ment, which involves giving therapeutic doses to
vulnerable groups (infants and pregnant women) at
regular intervals, regardless of infection status. In contrast
to previous studies, we also tested parasite lines isolated
from natural infections in a population where exposure
to anti-malarial drugs is frequent. We used drug-sensitive
and drug-resistant lines to test whether parasites alter
their investment as a general response to the presence of
drugs or only when vulnerable to drug treatment.
2. MATERIAL AND METHODS
(a) Parasites and cultures
The initial isolates were obtained with informed consent
from patients in Asar village in Eastern Sudan. In this
region, malaria transmission is markedly seasonal, following
the rainy season (September to November). Plasmodium
falciparum is the predominant parasite species, and treatment
with chloroquine and/or pyrimethamine is frequent in the
transmission season (Babiker et al. 1991). We established
each isolate in in vitro culture according to Jensen & Trager
(1977), using narrow-necked culture ﬂasks. Brieﬂy, each cul-
ture consisted of 5 ml complete culture medium, containing
RPMI supplemented with 25 mM NaHCO3 (Sigma, UK),
25 mM 4-(2-hydroxyethyl)-l-piperazineethane-sulphonic
acid (Sigma, UK), 10 per cent naive human serum, adjusted
to pH 7.4, gassed with a mixture of 3 per cent O2, 5 per cent
CO2 and 92 per cent N2, and sealed throughout incubation.
We obtained distinct experimental lines by limiting dilution
from isolates exhibiting diversity for genetically controlled
traits including sensitivity to chloroquine and pyrimethamine
(Babiker et al. 1991; Bayoumi et al. 1993). We obtained three
lines sensitive to both chloroquine and pyrimethamine (iden-
tity codes: 107/89, 109/89, 104/89) and three lines resistant
to both drugs (124/8, 121/89, 123/89).
(b) Experimental procedures
We established three replicate cultures for each of our three
drug-sensitive and three drug-resistant lines, and allocated
one replicate per line to each of the following treatments:
no-drug control, chloroquine-treated and pyrimethamine-
treated. Therefore, we followed a cross-factored design in
which parasites from each line experienced all experimental
treatments. We set up each line/treatment combination in
duplicate or triplicate, resulting in six to nine cultures for
each of our six lines, totalling 39 cultures. We followed
Carter et al. (1993) to establish gametocyte-producing cul-
tures: as soon as 5 per cent of RBCs were parasitized, 1 ml
(5%) was added to 4 ml of 6 per cent haematocrit-uninfected
blood, in media appropriate to the treatment group for each
culture (media without drugs, with 0.5 pmol chloroquine or
with 0.5 nM pyrimethamine) and the haematocrits of all cul-
tures were set to 6 per cent (no further RBCs were added
during culturing). The doses of chloroquine and pyrimetha-
mine we used are low: the minimum doses required to clear
all sensitive parasites are 8 pmol and 10
25 M, respectively. We
maintained cultures for 11 days and replaced culture medium
daily with either drug-free or drug-containing media accord-
ing to the treatment for each culture.
We sampled cultures daily using Giemsa-stained thin
blood smears and recorded the parasitaemia, the numbers
of ring stages and stage 2 gametocytes per 10 000 RBCs.
We used these values to calculate the gametocyte conversion
rates for each culture from day 0 to day 8, following Carter &
Miller (1979). The gametocyte conversion rate (reproductive
effort) represents the proportion of a cohort of asexually
produced ring-stage parasites that become sexual-stage
gametocytes. After invading an RBC, parasites spend their
ﬁrst 24 h as ring stages, which can be readily distinguished
in blood smears. Gametocytes cannot reliably be distin-
guished by morphology until they have reached stage 2 of
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version rate on day t is simply calculated as the number of
stage 2 gametocytes observed in 10 000 RBCs on day t þ 2
divided by the number of ring-stage asexual parasites
observed in 10 000 RBCs on day t. Unlike in vivo infections,
in vitro culture is ideal for calculating conversion rates
because all parasites of all developmental stages are accessi-
ble for sampling (gametocytes cannot sequester in tissues
and asexuals are not exposed to attack from immune factors),
so potential problems such as stage-speciﬁc mortality cannot
confound estimates.
(c) Statistical analysis
We used R v. 2.5.0 (The R Foundation for Statistical
Computing, Vienna, Austria) for all analyses. We log-
transformed conversion rates to conform to the assumptions
of parametric tests and used linear mixed-effects models
with maximum likelihood to investigate the effects of drug
treatment and drug sensitivity on the patterns of conversion
rates observed during cultures, according to the three sets
of analysis described below. Mixed-effects models allowed
each culture to be nested within the identity of the line con-
tributing the parasites while ﬁtting line identity as a random
effect, which can account for problems of non-independence
associated with repeated measures in longitudinal analyses.
We nested culture within the identity of each line for all
analyses and evaluated the signiﬁcance of ﬁxed effects by com-
paring models using log-likelihood ratio tests following
stepwise deletion of the least signiﬁcant term. Speciﬁcally,
we compared the change in model deviance, following term
deletion, to x
2 distributions with degrees of freedom corre-
sponding to the difference in the number of terms in the
models. We simpliﬁed maximal models until only signiﬁcant
terms remained in the model (Pinheiro & Bates 2000).
Minimal models from our different analyses were compared
with log-likelihood ratio tests and Akaike information criteria
(AIC). We then re-ran our ﬁnal minimal model using
restricted maximum likelihood to estimate the effect sizes
and plot model predictions.
We ran three sets of models to ﬁnd the most parsimonious
description for the inﬂuences of drug treatment and suscep-
tibility to drugs on the patterns of gametocyte conversion
rates observed during cultures. By comparing models in
which we combined different factor levels and different treat-
ment groups, we tested whether gametocyte conversion rates
differed between cultures according to the type of drug used
and the susceptibility of parasites. In addition to testing for
the effects of drug treatment or drug sensitivity, we also
ﬁtted RBC density as a covariate in all maximal models as
host anaemia has been shown to inﬂuence conversion rate
during in vivo infections (Reece et al. 2005). In all analyses,
day was ﬁtted as a covariate. To test whether patterns of
conversion were nonlinear, each maximal model contained
both linear and quadratic terms for day, but, in all models,
all interactions and main effects for the quadratic were
non-signiﬁcant (p . 0.05).
In our ﬁrst analysis, we speciﬁed drug treatment as a ﬁxed
factor with three levels (chloroquine, pyrimethamine,
control) and we speciﬁed whether parasites were resistant
or sensitive as a ﬁxed factor with two levels. Second, we
tested whether the type of drug mattered by combining the
chloroquine and pyrimethamine cultures and ﬁtting drug
treatment as a ﬁxed factor with two levels (drugs, control).
Third, we investigated whether our analysis could be simpli-
ﬁed further by testing whether gametocyte conversion rates
only differed between sensitive parasites in drug-treated cul-
tures and all other groups that were either in control cultures
or resistant to drugs. We ﬁtted this as a ﬁxed factor with two
levels, by classifying parasites as safe (i.e. combining control
cultures and resistant lines in drug-treated cultures) or
vulnerable to drugs in their cultures (i.e. only sensitive lines
in drug-treated cultures). By comparing the resulting
minimal models from these three analyses, we obtained the
most parsimonious description of conversion rates without
signiﬁcant loss of explanatory power. Finally, we tested
whether the ﬁxed effects providing the best description of
conversion rates also inﬂuenced the densities of gametocytes
and asexual stages observed during days 1–8 in the cultures.
3. RESULTS
Our ﬁrst analysis revealed that the patterns of conversion
rates observed during cultures were signiﬁcantly inﬂu-
enced by the interaction between treatment, the drug
sensitivity of parasites and day (x
2
2 ¼ 6.49; p ¼ 0.039),
but not by RBC density (x
2
1 ¼ 0.96; p ¼ 0.328). Our
second analysis, in which we collapsed the chloroquine-
and pyrimethamine-treated groups into one factor level
(table 1), also revealed that patterns of conversion rates
Table 1. Model estimates (+s.e.) and signiﬁcance for the intercepts and slopes for transformed conversion rates examined in
our second analysis, revealing that the conversion rates of sensitive (vulnerable) parasites exposed to drugs are signiﬁcantly
lower than for other treatment groups (safe from drugs), and that conversion rates of parasites safe from drugs were not
signiﬁcantly different from each other. Estimates (+s.e.) given are relative to the conversion rates of the resistant parasites in
control cultures, and t- and p-values test the difference between the resistant parasites in control cultures and the other
groups.
tp
intercepts
resistant parasites without drugs 23.545 (+0.25)
D resistant parasites exposed to drugs 0.166 (+0.30) 0.56 0.578
D sensitive parasites without drugs 0.242 (+0.37) 0.66 0.543
D sensitive parasites exposed to drugs 0.400 (+0.44) 0.91 0.370
slopes
resistant parasites without drugs 0.278 (+0.04)
D resistant parasites exposed to drugs 20.007 (+0.05) 0.15 0.879
D sensitive parasites without drugs 20.007 (+0.06) 0.12 0.901
D sensitive parasites exposed to drugs 2 0.167 (+0.07) 2.41 0.017
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treatment and whether parasites were sensitive or resistant
(x
2
1 ¼ 5.81; p ¼ 0.016), but not by RBC density (x
2
1 ¼
0.82; p ¼ 0.365). We compared the minimal models for
our ﬁrst and second analyses (AIC ¼ 890.49 and
887.81, respectively), and found that there was no signiﬁ-
cant loss of deviance associated with the second, simpler
model (x
2
4 ¼ 5.32; p ¼ 0.256), revealing that patterns of
conversion rates did not signiﬁcantly differ according to
the type of drug parasites were treated with and that
resistant parasites do not alter their conversion rates in
response to drugs.
We then tested whether gametocyte conversion rates
simply depended upon whether parasites were both in
drug-treated cultures and susceptible to drugs. This
analysis revealed that parasites vulnerable to drugs in
their cultures (the sensitive lines in drug-treated cultures)
followed patterns with signiﬁcantly lower conversion
rates than parasites safe from drugs (ﬁgure 1;
x
2
1 ¼ 23.74; p , 0.0001). There was no additional
inﬂuence of whether parasites were drug-sensitive or
resistant (x
2
1 ¼ 0.34; p ¼ 0.557; interaction with day:
x
2
1 ¼ 0.81; p ¼ 0.367), nor of RBC density (x
2
1 ¼ 0.002;
p ¼ 0.969). Again, there was no signiﬁcant loss of
deviance when comparing the minimal models for
our second and third analyses (x
2
6 ¼ 0.76; p ¼ 0.944;
AIC ¼ 887.81 and 880.57, respectively). This shows
that conversion rates simply depend upon whether
parasites were vulnerable to, or safe from, drugs they
were exposed to in their cultures.
In addition, we investigated whether the densities of
gametocytes and asexual stages also differed according
to whether parasites were vulnerable to, or safe from,
drugs in their cultures. As expected, the lower conversion
rates observed when parasites were vulnerable to drugs
translated into the production of fewer gametocytes
compared with parasites safe from drugs (ﬁgure 2a;
x
2
8 ¼ 36.20; p , 0.0001). In contrast, while the densities
of asexual parasites varied during cultures (x
2
8 ¼ 164.11;
p , 0.0001), this was not signiﬁcantly inﬂuenced by
whether parasites were vulnerable to drugs (ﬁgure 2b;
x
2
1 ¼ 1.47; p ¼ 0.225; interaction with day: x
2
8 ¼ 8.63;
p ¼ 0.374). Moreover, the asexual densities of the sensi-
tive lines did not differ signiﬁcantly between treatments
(x
2
1 ¼ 1.65; p ¼ 0.199).
4. DISCUSSION
We tested whether multiple lines of the human malaria
parasite (P . falciparum) facultatively alter their allocation
of resources to between-host transmission (gametocyte
conversion rate) when exposed to low doses of different
anti-malarial drugs. Our analyses show that gametocyte
conversion rates were signiﬁcantly lower in the drug-
sensitive lines when exposed to drugs than for all parasites
lines in drug-free control cultures, and than for the drug-
resistant lines in drug-treated cultures (ﬁgure 1). Put
simply, only the drug-sensitive lines decreased their invest-
ment into transmission stages when exposed to drugs.
These data reveal that, as predicted, parasites adopt repro-
ductive restraint when stressed by low doses of drugs.
The drug-resistant lines did not signiﬁcantly alter their
conversion rates when exposed to drugs (and their
conversion rates were not signiﬁcantly different from the
sensitive lines in control cultures), suggesting that parasites
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Figure 1. Means+s.e. gametocyte conversion rates (calcu-
lated as the proportion of ring stages from each asexually
produced cohort that committed to becoming gametocytes)
observed during cultures for drug-sensitive and drug-resist-
ant isolates when exposed to anti-malarial drugs or control
conditions. Conversion rate signiﬁcantly differed according
to whether parasites were ‘safe’ or ‘vulnerable’ to any drugs
in their cultures. Parasites safe from treatment included
those in control cultures (white squares, sensitive lines;
white circles, resistant lines) and resistant parasites in drug-
treated cultures (black circle), whereas vulnerable parasites
are the drug-sensitive parasites exposed to drugs (black
squares). Therefore, only the sensitive parasites altered
their conversion rates when exposed to drugs. Best-ﬁt lines
are from the minimum adequate model for parasites
vulnerable to drugs (solid line) and safe from drugs
(dashed line).
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Figure 2. (a) Means+s.e. per cent of RBCs infected with
gametocytes (gametocytaemia) and (b) ring-stage asexually
produced parasites (parasitaemia) during cultures for drug-
sensitive (squares) and drug-resistant (circles) lines when
exposed to anti-malarial drugs (black symbols) or control
conditions (white symbols).
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conversion rates in response to changes in their prolifer-
ation (Koella & Antia 1995; Paul & Brey 2003).
Information about their absolute density, or changes in
density, could be obtained through a form of quorum sen-
sing (Dyer & Day 1993) or the presence of lysed parasites,
and other studies also suggest that parasites respond to
their own density (Reece et al. 2008; Pollitt et al.
submitted). Alternatively, as our lines were isolated at a
time of frequent exposure to drugs, it is possible that
the sensitive lines have evolved a speciﬁc response to
these drugs, which the resistant parasites either never
had or have subsequently lost. The latter could occur if
there are costs associated with maintaining unnecessary
information-gathering and processing systems (DeWitt
et al. 1998). Investigating how parasites respond to
drugs with different modes of action and different target
stages could resolve this.
Our data reveal that parasites adopt reproductive
restraint when exposed to low doses of anti-malarial
drugs. This response is consistent with the hypothesis
that reducing investment in gametocytes enables parasites
to prioritize their survival by increasing their replication
rate (Roff 1992; Stearns 1992; Koella & Antia 1995;
Mideo & Day 2008; Fischer et al. 2009; McNamara
et al. 2009). The asexual densities of sensitive strains
were not signiﬁcantly reduced in the drug-treated cul-
tures, and we suggest that reproductive restraint enabled
these parasites to reduce the detrimental effect of drugs.
Quantifying the survival advantage gained by reducing
investment in gametocytes requires experiments that
measure the ﬁtness consequences for parasites unable to
respond to drugs, which in turn requires indentifying
the mechanism parasites use to measure and respond to
stress. This is also an area where mathematical modelling
would be very useful. By calculating how much replication
can be increased for a given reduction in gameto-
cyte investment, the optimal strategy for parasites
experiencing different probabilities of survival can be pre-
dicted. This would reveal whether parasites should switch
from reproductive restraint to terminal investment, and
where this threshold lies. More broadly, combining exper-
iments and models in this way could provide novel insight
into the costs and limits of phenotypic plasticity (Auld et al.
2009; McNamara & Houston 2009). Alternatively, it may
be the case that our low drug doses were not harmful to the
sensitive strains. However, this explanation is not as parsi-
monious, because it is not clear why the sensitive parasites
would respond to drugs that are not harmful, and suggests
that sensitive parasites respond to the presence of drugs, in
which case it is not clear why the resistant parasites do not
respond to drugs too.
Previous studies have revealed that malaria parasites of
rodents and humans increase their investment in gameto-
cytes when exposed to doses of drugs. Why have we
recovered the opposite result? In addition to previous
studies using higher doses and applying them for a
short time, we outline three other explanations, which
may not be mutually exclusive, below. First, our in vitro
approach and analysis of patterns of conversion differ
from previous studies. Parasite behaviour varies consider-
ably during in vivo infections, and even with seemingly
simple experimental manipulations, variation in poten-
tially confounding factors (e.g. changes in RBC age
distribution, anti-gametocyte immunity) can also occur
(Reece et al. 2005, 2009; Long et al. 2008; Mideo et al.
2008). In natural infections, drug treatment often
coincides with, and can alter, the development of disease
symptoms, including anaemia (Ekvall et al. 1998), which
could confound apparent responses to drug treatment.
While the inﬂuences of these factors could be tested,
and potentially controlled for, they are rarely measured
as analyses are usually focused on summary or snapshot
data from infections.
Second, our results may differ from experiments with
rodent parasites (Buckling et al. 1997; Buckling & Read
1999) because the developmental schedules of rodent
and human parasites differ. The ability to match invest-
ment in gametocytes to in-host conditions may be
constrained by how much the in-host environment can
change during a cell cycle and during the maturation
period of gametocytes. The cell cycle of rodent parasites
is 24 h and gametocytes require less than 48 h to reach
maturity, whereas P . falciparum parasites only replicate
every 48 h and gametocytes require around 10 days
to reach maturity (Garnham 1966). Rodent malaria
parasites may be able to rapidly switch strategies, but
P . falciparum parasites might be constrained to playing
it safe and investing more in survival when in-host
conditions are changing.
Third, our results may differ from previous studies
with P . falciparum owing to variation in the ecology of
the populations that isolates were collected from. Previous
studies have used P . falciparum parasites from regions of
high prevalence and year-round transmission, which are
also well adapted to in vitro growth (Buckling et al.
1999b). Exposure to drugs may be a selection pressure
that is too novel for these parasites to respond optimally
to, and/or a fast drop in density may be used as a cue
that survival is unlikely. In contrast, our lines have been
maintained in an in vitro culture for only a limited time,
and were isolated from an area with low and seasonal
transmission, in which chronic infections are responsible
for much of the malaria transmission and anti-malarial
drug use is common (Babiker et al. 1991, 1998). Parasites
in areas of high transmission may beneﬁt from a ‘live fast,
die young’ life history (Lines et al. 1991), but the value of
future versus current reproduction is likely to be much
higher for our parasites, and so they should be more
likely to invest in survival when stressed.
Observations of changes in gametocyte carriage follow-
ing drug treatment of natural infections in eastern
Sudan—the region from which our parasites were
isolated—are consistent with our results (Nassir et al.
2005; Ali et al. 2006). This issue is controversial because
is not clear whether elevated gametocyte densities
observed in natural infections after drug treatment are
due to a change in investment or simply due to the release
of sequestered gametocytes (Drakeley et al. 2006; Babiker
et al. 2008). Our data suggest the latter, and if this occurs
in natural infections, there will be implications for under-
standing and predicting the spread of drug resistance
(Read & Huijben 2009). By reducing conversion rates
in response to drug treatment, drug-sensitive parasites
may transmit at a slower rate than drug-resistant parasites
during exposure, but will be more likely to survive and,
thus, transmit over a longer duration than currently
expected. Determining whether the response of sensitive
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inﬂuence their proliferation or a speciﬁc adaptation to
drugs now is central to predicting the behaviour and evol-
utionary trajectories of parasites in populations with
different exposure to drugs and transmission patterns.
The opportunity to combine experiments with ﬁeld data
for the same population of human parasites offers a
promising way to further the ﬁeld of evolutionary
medicine (Williams & Nesse 1991; Stearns & Koella
2007). Mathematical models, experiments and ﬁeld
data are now required to determine how parasite
investment strategies inﬂuence the maintenance of drug-
sensitive parasites in natural populations, how their
investment strategies vary with the magnitude and form
of the stress they experience, and what the implications
are for their virulence (Schneider et al. 2008). More
generally, using an evolutionary approach to explain
virulence hinges on the useful application of life-history
trade-offs to parasites (Day 2003; Alizon et al. 2009).
By revealing that malaria parasites trade off survival and
reproduction in the manner explained by evolutionary
theory for life histories, we can be more optimistic
about understanding virulence.
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